×

Biogen brawl

4:43 PM ET Tue, 22 Dec 2015

Michael Yee, RBC Capital Markets, has a $450 price target on Biogen and Andrew McDonald, co-portfolio manager of Bioshares fund, says Biogen is the best short in Biotech.